Advancing Obesity Care

Beyond GLP-1s.

SANA’s novel mechanism targets energy balance through thermogenesis, offering a new pathway for effective, sustainable weight management. Designed to address unmet needs for patients who may not benefit from or tolerate current therapies

About us

Eolo Pharma is a clinical-stage biotechnology company pioneering new approaches to treat obesity and metabolic disease. By targeting the body’s energy expenditure pathways, we aim to develop transformative therapies that go beyond traditional weight-loss mechanisms. Our lead candidate, SANA, is the first compound shown to safely activate creatine-dependent thermogenesis in humans, a novel biological process with the potential to reset metabolic health. Backed by over a decade of research, our work reflects a commitment to advancing science-driven solutions that improve lives worldwide.

Our

Pipeline

Our NCE library is composed of 60 novel molecules. Within our pipeline we highlight MVD1, our lead compound for Obesity and its comorbidities.

Indications
Program
Drug Candidate
Discovery & chracterization
Phase I
Phase II
Phase III
Obesity T2 Diabetes NASH Hypertension
Oral thermogenic NCE
MVD 1 analog
NCE
ALS Alzheimer's
NF-kB inhibitor & other
Eolo40
MVD-1

Our Science

At Eolo Pharma, we apply state-of-the-art biomedical research and mechanism-based drug design to develop first-in-class therapies targeting energy balance and metabolic dysfunction.

Our work is rooted in unlocking underexplored biological pathways to deliver scientifically validated treatments that improve patient outcomes worldwide.

Research at Eolo

Discover our collection of peer-reviewed publications, unveiling groundbreaking research in various fields. Engage with our insightful works that bridge science and innovation, offering valuable insights into obesity, ALS, and tissue transplantation. Join us in exploring the forefront of knowledge and unlocking new possibilities in healthcare.

Latest Publication

Nature Metabolism: A nitroalkene derivative of salicylate, SANA, induces creatine-dependent thermogenesis and promotes weight loss

Partners & supporters